首程控股（00697.HK）迎来国际长线接盘 机器人产业生态进入价值收割期 ACN Newswire

首程控股（00697.HK）迎来国际长线接盘 机器人产业生态进入价值收割期

February 24, 2026
香港, 2026年2月25日 - (亚太商讯 via SeaPRwire.com) - 今日，市场关注到首程控股（00697.HK）股价出现一定波动，叠加个别股份变动安排，引发部分投资者讨论。综合公司近期公告、公开行情数据及市场结构变化情况来看，相关波动更多体现为阶段性资金博弈。在资本结构持续优化、产业主线逻辑清晰的背景下，公司基本面未发生实质性变化。市场人士透露，在近期市场调整过程中，部分国际长线资金通过协议及大宗方式完成战略性布局，实现了筹码结构的有序转换。相关观点认为，这种"短期筹码向长期资本转移"的过程，有助于平滑阶段性流动性波动，同时提升股东结构的稳定性与质量。从资金属性看，长线资本的进入往往意味着对公司中长期成长路径与价值兑现能力的认可，为后续估值修复奠定更加坚实的资金基础。从资本市场运行规律来看，当企业战略转型逐步进入成果兑现阶段时，股东结构的优化与再平衡往往同步发生。本轮结构调整所释放的核心信号在于，国际资金正以更为积极的姿态参与公司成长进程，认可其由传统资产管理平台向"硬科技产业生态构建者"升级的战略方向。这种资本与产业逻辑的共振，有助于强化市场对公司长期价值的认知与定价信心。外资机构的逆势买入，其逻辑支撑源于首程控股基本面的深刻蜕变。公司正从传统的资产管理平台，成功向"产业生态构建者"转型。通过独特的"资本+场景+运营"三维模式，首程控股已构建起闭环生态，特别是在机器人赛道的前瞻性布局，已使其成为港股硬科技投资的标杆。2026年被市场普遍视为具身智能与人形机器人商业化加速落地的重要时间窗口。首程控股前期在机器人赛道的系统性布局，正在进入集中收获期，机器人赛道整体投资回报表现亮眼：核心项目实现高溢价： 依托对自变量科技、宇树科技等领军企业的早期重仓已实现显著账面增值，随着宇树科技等明星项目正式开启IPO冲刺，首程控股持有的股权将迎来从"账面浮盈"向"现金分红"的实质性跨越，持续增厚上市公司利润。此外，值得关注的是，在2026年马年央视春晚舞台上，宇树科技、银河通用、松延动力等机器人企业集体亮相，展示了具身智能技术在复杂动作控制与人机交互方面的突破。这不仅强化了公众认知，也标志着相关企业已进入规模化应用前夜。作为上述企业的重要早期布局方，首程控股间接受益于产业热度与商业化进程提速带来的估值重估。市场分析人士表示，今日的市场交易将促使公司股东结构更趋多元化。国际长线资金的进入，一方面提升了股票的全球流动性基础与治理透明度预期，另一方面也为未来产业扩张提供更广泛的资源协同空间。从市场经验看，当企业基本面处于上行周期且结构性不确定性逐步消除时，股东结构的优化往往成为估值修复的重要触发因素。分析人士指出，本轮筹码调整本质上是资本结构的战略再平衡，为公司进入价值兑现周期扫清短期供给压力。综合来看，首程控股当前处于三重拐点叠加阶段，首先是产业拐点—具身智能与机器人商业化加速；其次是资本拐点—投资项目进入集中兑现期；再次是结构拐点—国际长线资本入场优化股东结构。在国际资金认可与产业价值红利共振之下，公司估值逻辑正从"传统资管估值框架"向"硬科技产业平台估值框架"切换。随着产业落地与资本回报逐步兑现，市场对于首程控股作为"智能时代产业基础设施构建者"的认知将进一步强化，其长期价值重塑进程或已进入实质性阶段。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
特朗普国情咨文宣布授予美国冰球守门员康纳·赫勒比克总统自由勋章 Latest News

特朗普国情咨文宣布授予美国冰球守门员康纳·赫勒比克总统自由勋章

February 24, 2026
(SeaPRwire) - 在唐纳德·特朗普国情咨文演讲的开始阶段，总统：美国人在他的领导下会赢得如此之多，以至于他们会感到厌倦。 “我们的国家正在再次获胜，”特朗普夸耀道。“事实上，我们赢得如此之多，以至于我们真的不知道该如何应对。” 作为该国连胜势头的主要证据，他随后在众议院会议厅欢迎了美国男子国家冰球队，“他们让整个国家感到自豪”，在周日的2026年米兰冬奥会决赛之后他们 。FBI局长 在决赛后的更衣室里。 特朗普谈到观看这场比赛对他来说有多激动，特别提到了康纳·赫勒布伊克的出色表现，称他“从未见过有守门员打得像赫勒布伊克一样好”。赫勒布伊克为美国队挡下了41次射门。 [video id=d9uQ0GmW autostart="viewable"] “我问他，‘那一球，就是你把球杆放在背面，球击中球杆颈部后弹开的那一球，你是练过的还是有点运气成分？’”特朗普说。“他拒绝回答这个问题。” 特朗普随后表示，他将很快向赫勒布伊克颁发美国政府最高平民荣誉：总统自由勋章。此前获得该勋章的运动员包括高尔夫球手泰格·伍兹、篮球运动员迈克尔·乔丹和卡里姆·阿卜杜尔-贾巴尔，以及棒球传奇威利·梅斯。 “伟大的运动员获得过这一荣誉——非常伟大，最顶尖的——我认为他当之无愧，”特朗普在谈到赫勒布伊克时说。“你完成了一项多么特别的任务，你们是何等特别的冠军。” 特朗普还向美国女子奥运冰球队致敬，她们也 特朗普表示，这支女子队伍——曾 特朗普出席国情咨文的邀请，USA Hockey的一位发言人 “此前已安排好的赛后学术和职业事务”——将“很快”访问白宫。本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Saisi 将参加 MWC2026 巴塞罗那展会：提供先进的时频及语音通信解决方案 Finance

Saisi 将参加 MWC2026 巴塞罗那展会：提供先进的时频及语音通信解决方案

February 24, 2026
(SeaPRwire) - 中国嘉兴，2026年2月25日 -- 中国自主研发的时频和通信芯片领域的关键先驱浙江赛思，将于3月2日至5日在巴塞罗那Fira Gran Via举行的MWC2026（“智商时代”）展会上，在5号馆5J64展位，展示其核心语音通信和时频同步解决方案，届时将展出其自主研发的高端芯片和解决方案。 在语音通信方面，赛思将展示面向10G PON/FTTR设备的完整FXS单/双通道解决方案以及自主研发的SLIC芯片（AS1630、AS2630系列）。作为中国首家自主研发SLIC芯片的企业，赛思解决了行业关键瓶颈，提供了具有成本效益的用户线路接口解决方案。 一个关键亮点是其端到端时频同步解决方案，包括全系列晶体振荡器。其新型超低抖动差分振荡器（25MHz~625MHz，在156.25MHz下为44fs）为高性能AI设备和5G-A/6G基站提供了卓越的精度，同时还为关键场景提供原子钟、时钟模块和时钟系统。 凭借自主研发的核心算法（FPGA时序、TDC、卡尔曼滤波）和集成定制能力，赛思的产品已销往30多个国家，巩固了其在中国时频领域的关键地位。参加MWC2026是其全球扩张的重要一步。 赛思诚邀全球合作伙伴莅临5号馆5J64展位，体验其产品，并共同探索AI驱动的连接合作。 公司简介： 浙江赛思电子科技有限公司成立于2013年，专注于时频同步和通信集成电路，具备从核心芯片到系统解决方案的全方位能力。公司是中国时频行业和国内SLIC芯片领域的领先企业。 其解决方案涵盖三大核心领域：面向5G/6G、智能电网、轨道交通和金融数据中心的时频同步；面向AI计算、数据中心和工业自动化的 Saisi 高性能时钟芯片；以及基于自主研发SLIC芯片的用户线路接口解决方案，为PON、VoIP网关、XDSL、FTTR、企业电话和接入设备提供高度集成、低功耗、可靠的电话线路接口。 公司致力于自主研发，拥有核心时序和芯片技术以及广泛的知识产权，并积极参与行业标准制定和协同创新。 公司：Zhejiang Saisi Electronic Technology Co.,Ltd. 联系人：Chaos Zhang 邮箱：sales@zjsaisi.com 网址：www.saisisync.com 电话：+86 15268307576 城市：中国嘉兴 随此公告发布的是一张图片，可在此处查看：. 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu’s IoT Visualization Solution JCN Newswire

Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu’s IoT Visualization Solution

February 24, 2026
Kawasaki, Gunma, Japan, Feb 25, 2026 - (JCN Newswire via SeaPRwire.com) - BEISIA CO., LTD. and Fujitsu Limited today announced that both companies have begun introducing and operating Fujitsu's Advanced Operation & Management offering for digitalizing stores and improving labor productivity at Beisia stores. This solution, part of Fujitsu’s Uvance business model, is being used to automate the temperature management of refrigerator and freezer facilities within stores. The companies plan to implement the solution in all 138 Beisia stores across Japan by May 2026.Introduction of the solution commenced in December 2025This initiative will streamline operations for store employees in complying with HACCP requirements(1), enhancing product freshness management and reducing food loss by providing alert notifications when abnormalities exceeding set thresholds are detected.Under its Uvance business model, which addresses societal challenges, Fujitsu will leverage the knowledge and experience gained from implementing Advanced Operation & Management at Beisia to drive the digitalization of stores through data and AI, enhance labor productivity and promote sustainable store operations.OverviewPrior to the full-scale rollout, Beisia conducted a practical verification of the solution at its Beisia Foods Park Takasaki Kuragano store (Takasaki City, Gunma Prefecture). After confirming the effectiveness of temperature data acquisition and management, as well as the efficiency gains for employees, Beisia decided to implement the solution across all its stores, with sequential deployment beginning in December 2025.Fujitsu's Advanced Operation & Management is a solution that visualizes data acquired from various IoT sensors in real-time. A key feature is its rapid deployment and operation through the attachment of IoT sensors to existing equipment, without dependency on specific hardware.At Beisia, IoT sensors attached to refrigeration and freezing equipment throughout the stores will extract and visualize temperature information in real-time. This eliminates the need for manual inspection and recording by store employees, significantly reducing their workload.Moreover, when abnormalities exceeding thresholds or conditions are detected, alerts are promptly sent to the store's operational communication tools. This enables quicker initial responses to anomalies, strengthening product freshness management, and reducing food loss. Additionally, both headquarters and individual stores can access the same real-time information via a dashboard, facilitating centralized management of information from multiple stores and supporting overall store operation optimization.In Japan, the revised Food Sanitation Act(2) mandates the implementation of HACCP, an international standard for food hygiene management, for all food-related businesses. In the supermarket retail industry, thorough temperature management is crucial for product freshness and consumer trust. However, with a severe labor shortage, streamlining inspection and recording tasks has become an urgent issue.Previously, Beisia stores manually recorded temperatures twice a day for an average of 150 refrigeration and freezing units per store, posing a significant workload for employees. Against this backdrop, Beisia decided to introduce a solution to automate temperature management for its in-store refrigeration and freezing equipment.Figure 1: Overview of Fujitsu's IoT Visualization SolutionFigure 2: IoT Sensor installed in a Beisia store freezer(1) HACCP (Hazard Analysis and Critical Control Point):A food hygiene management method that ensures product safety by identifying and managing critical control points throughout the entire food production process, from raw material reception to product shipment, to eliminate or reduce hazards such as food poisoning bacteria contamination and foreign object mixing.(2) Revised Food Sanitation Act:A law designed to ensure food safety in response to changes in the food environment and globalization. Revised in 2018, it mandated HACCP implementation.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准 ACN Newswire

国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准

February 24, 2026
香港, 2026年2月25日 - (亚太商讯 via SeaPRwire.com) - 2月23日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK））宣布，已正式获得香港证券及期货事务监察委员会（SFC）批准，自2026年2月12日起可在其两家持牌机构（国泰君安证券（香港）有限公司及国泰君安外汇有限公司）采用国际掉期与衍生工具协会ISDA标准初始保证金模型（Standard Initial Margin Model, "SIMM" ）计算场外衍生品交易的初始保证金。ISDA SIMM 是业界通用的标准方法论，专门用于计算非集中清算衍生品的监管初始保证金。该模型通过建立统一的计算标准，使所有市场参与者得以遵循同一框架进行保证金核算，不仅避免了各机构独立开发模型所产生的额外成本，还有效减少了因算法差异引发的潜在争议。其配套的治理框架进一步确立了行业共同实践，确保保证金计提既符合全球监管要求，又充分保障了保证金的充足性。此次获批标志着国泰君安国际场外衍生品业务的风险管理能力迈上新台阶，在巩固合规与风控标杆的同时，显著提升中资券商国际化竞争力。通过采用国际市场通行的SIMM模型，公司得以接轨国际大行标准，能够更精准、高效地管理初始保证金，在有效控制交易对手风险的同时，显著节省交易成本，实现更高资本效率，增强与全球机构对手方的合作信任，从而提升业务的长期竞争力。此次获批不仅是对公司衍生品业务技术实力的认可，更是监管机构对公司内部控制、尤其是风险管理能力的又一里程碑式肯定。展望未来，国泰君安国际将进一步精进衍生品业务的内控管理体系，筑牢长远稳定发展的根基。同时，作为香港资本市场的重要一员，公司将一如既往地配合监管机构，深度参与市场基础设施建设，助力提升香港场外衍生工具市场的国际竞争力与活力。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球81%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China SeaPRwire

CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

February 24, 2026
SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/
More
Hong Kong Tech Delegation Heading for Market Expansion at Mobile World Congress 2026 JCN Newswire

Hong Kong Tech Delegation Heading for Market Expansion at Mobile World Congress 2026

February 24, 2026
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – Hong Kong Trade Development Council (HKTDC), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), will lead a delegation of 21 Hong Kong tech companies and institutions to showcase at Mobile World Congress (MWC) 2026—the world’s premier connectivity event, and debut at 4 Years From Now (4YFN) 2026—a global stage for start-ups, taking place concurrently 2-5 March in Barcelona, Spain. Building on the momentum from MWC 2025, the Delegation will be featuring solutions beyond the Connectivity category, covering focus areas across Devices and Systems, Digital Transformation and support from Ecosystem Partners. The Pavilion duet ought to give a more comprehensive picture of Hong Kong’s innovation and technology (I&T) capabilities in engaging global telecom leaders, enterprise decision-makers, industry partners, and investors, bridging cutting-edge research and development (R&D) into real-world applications and propelling Hong Kong’s I&T sector onto the international stage.Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “The Hong Kong Tech Pavilion is an ideal platform for Hong Kong tech enterprises to present their latest R&D achievements at major international tech gatherings, support their journey to explore overseas markets, while highlighting Hong Kong’s strengths as an international innovation and technology hub.”Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC is a global bellwether for communications technology and tech companies at any stage, to connect with the industry and investors, to have a solid ground that validate solutions, catalyse pilot projects, accelerate commercialisation, and scale internationally.”A series of dialogues and exchanges, spanning from networking reception and themed talks to pitching sessions, will take place throughout the events at the Pavilion to facilitate partnerships and investment opportunities for innovative solutions that are market-ready with high potential for market expansion, in particular, Asmote and Cresento under “Connectivity” make stellar examples of the notion:5G & 6G for Communication, Sensing, and AI computing – Shannon & Turing, (Asmote), located at MWC, specialises in mmWave technology for Integrated Sensing and Communication (ISAC) technology—drone communications and control—rising to the occasion as the city advances its low-altitude economy initiatives, while winning favors for its efficiency in managing industrial scenarios such as smart ports and dark factories. The company previously secured the world’s first 26GHz mmWave 5G commercial communications project, demonstrating its leadership in industrial-grade applications.Smart Performance Insights for Sport – Cresento, located at 4YFN, focused on developing an AI-powered shin guard to deliver real-time insights—performance analytics, team leaderboards, and more—with a design that incorporates into gears that athletes already wear and creates minimal friction for, in particular, football players to adapt, will be moving from prototypes to pilot collaborations with European football clubs, academies and sport tech platforms and distributors.HKTDC continues to join hands with HKSTP to support Hong Kong tech enterprises to “go global” by jointly organising the Hong Kong Tech Pavilion to build bridges linking tech companies with the world. This expedites the industry’s progress in internationalisation to meet the growing demand for I&T globally. This will attract talents, facilitate forward-looking investments and explore opportunities globally, realising the mission of entrepreneurs to reach out to the world and further consolidate Hong Kong’s position as an international I&T hub.Mobile World Congress Barcelona (MWC) & 4 Years From Now (4YFN)Date: 2-5 March 2026Venue: Fira Gran Via, Av. Joan Carles I, 64, 08908 L'Hospitalet de Llobregat, Barcelona, SpainHong Kong Tech Pavilion:MWC – Booth 6E44 at Hall 64YFN – Booth 8.1B31 at Hall 8.1Please visit https://bit.ly/MWC2026HKTech for more information on Hong Kong Tech Pavilion and the exhibitors.Full list of 21 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026 (in alphabetical order):MWC 2026 - Booth 6E44 at Hall 61 Entoptica Limited Devices & Systems2 eSIX Connectivity3 Faraconix Technologies Co., Ltd. Connectivity4 FreightAmigo Services Limited Digital Transformation5 Glassdio Scientific Company Limited Connectivity6 Harvest Elite International Limited Digital Transformation7 HongKong Umedia Limited Devices & Systems8 iASPEC Services Limited Digital Transformation9 InvestHK Ecosystem Partners10 Robocore Technology Limited Devices & Systems11 Shannon & Turing Technology Limited Connectivity12 The Hong Kong Polytechnic University Ecosystem Partners13 Xeroptix Technology Devices & Systems4YFN 2026 - Booth 8.1B31 at Hall 8.114 AIGM Limited Digital Transformation15 BWSea Technology (HK) Co., Limited Digital Transformation16 Cresento Limited Devices & Systems17 GoGoChart Technology Limited Digital Transformation18 HairCoSys Limited Devices & Systems19 KNQ Technology Limited Digital Transformation20 Solos Technology Limited Devices & Systems21 Vista Innotech Limited Devices & SystemsAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and around 2,600 technology companies from 24 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.More information about HKSTP is available at www.hkstp.org.Media Contact: Hong Kong Science and Technology Parks CorporationHong Kong Trade Development CouncilAngela LauTel: +852 6535 7611Email: angela.lau@hkstp.orgWinnie KanTel: +852 2584 4055Email: winnie.wy.kan@hktdc.org Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More

Antalpha 将于2026年3月3日公布2025年第四季度及全年财务业绩

February 24, 2026
(SeaPRwire) - 新加坡，2026年2月24日 -- Antalpha Platform Holding Company（纳斯达克股票代码：ANTA）（"Antalpha"或"公司"），一家领先的机构数字资产融资平台，今日宣布将于2026年3月3日美国股市开盘前公布其2025年第四季度及全年财务业绩。公司管理团队将于2026年3月3日美国东部时间上午8:00（或新加坡时间晚上9:00）举行电话会议，讨论财务业绩。 欲参加会议，请提前注册： 注册后，您将收到一封日历邀请电子邮件，其中包含拨入号码、密码和您的唯一访问PIN码。 网络直播可在访问。电话会议的重播也将在公司的投资者关系网站上提供。 关于AntalphaAntalpha是一家领先的金融科技公司，专注于为数字资产行业的机构提供融资、技术和风险管理解决方案。Antalpha通过Antalpha Prime技术平台提供比特币供应链和保证金贷款，该平台允许客户发起和管理其数字资产贷款，以及以近乎实时的数据监控抵押品头寸。 联系方式投资者联系人： 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

RF Acquisition Corp III宣布自2026年2月26日起其普通股和认股权开始分开交易

February 24, 2026
(SeaPRwire) - 新加坡，2026年2月24日 -- RF Acquisition Corp III（“公司”或“我们”）宣布，自2026年2月26日起，公司首次公开发行中售出的1000万个单位的持有者可以选择分别交易这些单位中包含的普通股和认股权。任何未拆分的单位将继续在纳斯达克股票市场有限责任公司（“纳斯达克”）的全球市场板块以代码“RFAMU”进行交易，拆分后的普通股和认股权预计将分别在纳斯达克以代码“RFAM”和“RFAMR”进行交易。 单位持有者需要让其经纪人联系公司的过户代理Continental Stock Transfer & Trust Company，以便将单位拆分为普通股和认股权。 这些单位最初是由公司通过承销发行提供的。EarlyBirdCapital, Inc.担任此次发行的唯一簿记管理人。与这些单位及相关基础证券有关的注册声明于2026年1月30日生效。 本新闻稿不构成出售要约或购买要约的邀请，在任何州或司法管辖区，在根据该州或司法管辖区的证券法进行注册或获得资格之前，此类要约、邀请或出售属非法行为的，不得进行这些证券的出售。 关于RF Acquisition Corp III RF Acquisition Corp III是一家空白支票公司，其业务目的是与一家或多家企业进行合并、股本交换、资产收购、股票购买、重组或类似的业务合并。虽然我们在识别和收购目标公司时不会局限于特定行业或地理区域，但我们打算将搜索重点放在亚洲深度科技领域的企业，包括人工智能、量子计算和生物技术。然而，我们不会与总部位于大中华区或大部分业务在大中华区的任何公司进行首次业务合并。 前瞻性声明 本新闻稿包含构成“前瞻性声明”的陈述，包括关于预计将单位拆分为普通股和认股权的陈述。无法保证单位会按所示方式进行拆分。前瞻性声明受众多条件的约束，其中许多条件超出了公司的控制范围，包括公司向美国证券交易委员会（“SEC”）提交的与公司首次公开发行有关的注册声明和最终招股说明书的风险因素部分中所述的条件。相关副本可在SEC的网站www.sec.gov上获取。除非法律要求，公司没有义务在本新闻稿发布日期之后对这些声明进行修订或更改。 投资者联系方式： Tse Meng Ng董事长兼首席执行官tsemeng.ng@ruifengwealth.com本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
Galaxy Payroll Group Renews Five-Year Strategic Cooperation Agreement with NIKE China Holding HK Limited (Macau Branch) JCN Newswire

Galaxy Payroll Group Renews Five-Year Strategic Cooperation Agreement with NIKE China Holding HK Limited (Macau Branch)

February 24, 2026
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – February 22, Galaxy Payroll Group Limited (NASDAQ: GLXG) (“Galaxy” or the “Company”), a Nasdaq-listed human resources solutions provider, today announced that it has formally renewed a five-year strategic cooperation agreement with NIKE China Holding HK Limited (Macau Branch) (“Nike Macau Branch”).Five-Year Renewal with Comprehensive HR Service CoveragePursuant to the agreement, the renewed cooperation term will commence on December 1, 2025 and continue through November 30, 2030. During this period, Galaxy will continue to provide Nike Macau Branch with a comprehensive suite of human resources outsourcing services, including local payroll processing, attendance and leave management, social security and tax compliance filings, as well as advisory services relating to labor regulations and employment policies.This integrated service model is designed to enable Nike Macau Branch to focus on its core retail and brand operations while enhancing overall organizational efficiency and compliance management.Strategic Renewal Reflects Client Confidence and Enhances Revenue VisibilityThe renewal marks an important milestone in the long-standing relationship between the parties and reflects the continued trust placed in Galaxy’s professional capabilities, compliance standards, and service delivery quality by a leading international brand.The execution of a multi-year agreement is expected to enhance the Company’s revenue visibility and cash flow stability over the next five years, further aligning with its capital markets strategy of building a high-quality, resilient, and sustainable business model. While the agreement provides for long-term cooperation, actual results may vary and remain subject to market and operational conditions.Local Expertise and Scalable Service Infrastructure as Core Competitive AdvantagesSince its establishment in 2013, Galaxy has focused on the Hong Kong and Macau markets while progressively expanding its cross-regional service capabilities. The Company has developed deep expertise in Hong Kong and Macau labor laws, taxation, and social security regulations, forming a strong local compliance foundation.Through a service framework that combines standardized operational processes with customized solutions, Galaxy delivers consistency and scalability across its client base. Its proprietary payroll and attendance management platform enhances operational efficiency while supporting data security and business continuity, serving as a key differentiator in attracting and retaining multinational enterprise clients.Throughout prior phases of cooperation, Galaxy has supported Nike Macau Branch in navigating complex employment and compliance environments. The Company’s solutions have demonstrated reliability in accuracy, responsiveness, and risk control, providing a solid foundation for this long-term renewal.Looking Ahead: From Service Delivery to Value Co-CreationEntering the new cooperation cycle, Galaxy intends to further optimize payroll workflows and intelligent attendance systems within the existing service framework. Through enhanced data integration and periodic management reporting, the Company aims to support the client’s ongoing efforts toward standardized and digitalized human resource management.The parties have also agreed to retain flexibility to expand the scope of services through supplemental agreements, enabling the partnership to evolve in alignment with the client’s business development.The renewal of this five-year strategic agreement not only represents long-term recognition of Galaxy’s professional value, but also underscores the sustainability of its business model. It is expected to further strengthen the Company’s brand presence in the Hong Kong, Macau, and broader Asia-Pacific human resources outsourcing markets, while serving as a replicable benchmark case for multinational retail, sports, and consumer brands.As global enterprises increasingly prioritize compliance efficiency, cost optimization, and organizational resilience, Galaxy continues to leverage its localized expertise, robust service infrastructure, and high-quality client base to build sustainable long-term growth momentum.The Company’s management commented: “We will continue to place service capability at the core of our growth strategy, deepen strategic cooperation with existing high-quality clients, and proactively expand relationships with multinational and regional enterprises that offer long-term value, with the goal of delivering steady and sustainable returns to our shareholders.”Contact informationJune TuoTel: +852-5983-9260Phone: +86-1392-3804-279Intelligent Joy Limited Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More

JIADE LIMITED 签署不具约束力的谅解备忘录以探索韩美科技投资

February 24, 2026
(SeaPRwire) - 中国成都，2026年2月24日 —— JIADE LIMITED (Nasdaq: JDZG)（“JIADE”或“该公司”）通过其位于中华人民共和国的子公司，为成人教育机构提供一站式综合教育支持服务，今日宣布其于2026年2月24日与 Chinalink Education Group（“Chinalink”）签署了一份非约束性战略合作谅解备忘录（“MOU”）。Chinalink 是一家总部位于韩国的教育品牌，专注于人工智能（AI）赋能的教育和文化交流项目。此次合作旨在探索高增长技术领域的跨境投资机会。 此项举措旨在建立在该公司此前宣布的与 Chinalink 的跨境合作框架之上，并反映了 JIADE 持续努力扩大其国际影响力并参与技术驱动增长机会的决心。 该谅解备忘录概述了双方建立专注于韩国-美国的合作的意向，旨在识别并投资具有可扩展商业模式和国际扩张潜力的韩国技术企业，包括已上市、可能寻求上市或可能正在准备潜在美国首次公开募股（作为其长期增长战略的一部分）的公司。 在拟议的框架下，双方打算： 探索建立高达500万美元的战略资金池，以支持对选定的韩国技术公司进行股权投资；专注于AI融合行业，包括智能机器人，如智能清洁机器人、养老和医疗保健机器人、安全监控机器人以及商业AI服务机器人；考虑对AI驱动的教育平台进行潜在投资，包括自适应学习系统、智能辅导平台、AI语言和认知训练技术以及跨境数字教育基础设施；以及建立联合投资审查机制，以评估潜在项目并监督资金部署。 此次合作旨在支持基本面强劲且具有全球增长潜力的公司，包括那些可能寻求国际资本市场机会的公司。该谅解备忘录反映了双方当前的意向，并不构成具有法律约束力的投资承诺。任何投资都将取决于进一步的谈判和最终协议的签署。 “此次战略合作可能为我们提供扩大跨境投资范围并与韩国创新技术公司接触的机会，”JIADE LIMITED 董事长兼联席首席执行官 Yuan Li 表示。“我们相信，将资本资源与技术驱动的增长机会相结合，可以创造长期价值。” 关于 JIADE LIMITED JIADE LIMITED (Nasdaq: JDZG) 为中国的成人教育机构提供一站式综合教育支持服务。通过其子公司，该公司提供以 Kebiao Technology Educational Administration Platform（“KB Platform”）为核心的软件驱动和服务型解决方案，该平台简化了招生、学生管理、学习进度跟踪、成绩查询和毕业管理。JIADE 还提供辅助服务，如入学前指导、考试培训、申请支持、辅导和考试管理。迄今为止，该公司已为中国各地的17多家成人教育机构和约80,000名学生提供了支持。 前瞻性陈述 本新闻稿包含前瞻性陈述。这些陈述涉及已知和未知的风险和不确定性，并基于公司对未来事件的当前预期和假设。前瞻性陈述可通过“预期”、“计划”、“打算”、“相信”、“可能”、“将”、“应该”、“能够”、“将”、“大约”、“评估”、“希望”、“预计”、“估计”、“项目”及类似表达等词语识别。实际结果可能因各种因素而与此类陈述存在重大差异。除法律要求外，公司不承担更新任何前瞻性陈述的义务。尽管公司认为这些前瞻性陈述中表达的预期是合理的，但它无法向您保证这些预期最终是正确的，公司提醒投资者实际结果可能与预期结果存在重大差异，并鼓励投资者查看公司向美国证券交易委员会提交的文件中可能影响其未来结果的其他因素。 如需更多信息，请联系：JIADE LIMITED投资者关系部Email: 投资者关系公司WFS Investor Relations Inc.Email: Phone: +1 (628) 283-9214本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
ChartGen AI 登顶 Product Hunt 榜首，从图表工具扩展至 AI 驱动的仪表盘、图表和 PPT Finance

ChartGen AI 登顶 Product Hunt 榜首，从图表工具扩展至 AI 驱动的仪表盘、图表和 PPT

February 24, 2026
(SeaPRwire) - 新加坡，2026年2月24日 -- AI驱动的数据可视化平台 ChartGen AI 近日在 Product Hunt 上发布，并获得了当日最佳产品第一名和当周最佳产品第二名的成绩，在数百个全球产品发布中脱颖而出。 这一里程碑延续了其前身 Ada 的强劲表现，并反映了团队在数据分析、数据可视化和AI应用领域日益增长的全球用户和开发者认可度： ● 当日最佳产品第一名 ● 当周最佳产品第一名 ● 当月最佳产品第二名 从 Ada 到 ChartGen AI：从图表生成到完整的数据沟通 作为 Ada 产品系统的下一代演进，ChartGen AI 不仅仅是一次品牌重塑或生成单个图表的工具。相反，它围绕一个核心使命构建：让数据更易于理解和沟通。 在实际工作流程中，用户常常面临以下挑战： ● 耗时的数据清理和准备工作 ● 复杂的图表和仪表板创建过程 ● 难以将分析结果转化为可用于演示的材料 ● 非技术用户参与数据分析的门槛高 为了解决这些问题，ChartGen AI 实现了工作流程自动化，使用户能够从原始数据快速生成： ● 图表 ● 交互式仪表板 ● 报告和演示材料 这使得团队能够更专注于洞察和决策，而不是手动格式化和制作。 新功能发布：AI PPT 和结构图 伴随其在 Product Hunt 的发布，ChartGen AI 还推出了两项主要功能升级： AI PPT 生成 用户可以将分析结果即时转换为结构良好、可用于演示的幻灯片，减少手动格式化，提高业务报告和团队沟通的效率。 结构图生成 ChartGen AI 现在支持自动创建流程图、架构图和关系图，帮助用户清晰地呈现数据逻辑、业务流程或系统结构。 通过整合图表、仪表板、图示和PPT生成功能，ChartGen AI 正在从单一的可视化工具演变为一个全面的数据沟通平台。 全球反响 在其 Product Hunt 发布期间，ChartGen AI 吸引了来自多个国家用户的关注。 围绕此次发布的早期讨论凸显了该平台对实用性和清晰度的重视，将其定位为一款专为日常运营使用而设计的轻量级商业智能助手。 用户特别指出了无需复杂设置或格式化即可生成简洁、可用于演示的图表的价值。该产品的预测分析和外部数据集成能力也被认为是规划、报告和绩效跟踪的有用工具。 展望未来 ChartGen AI 专为分析师、产品经理和商业专业人士设计，通过自动化工作流程，帮助他们将原始数据转化为清晰的图表、仪表板、图示和PPT演示文稿。 团队将其在 Product Hunt 上取得的成就视为一个早期的里程碑，而非最终目标。展望未来，ChartGen AI 将继续： ● 提升数据处理和可视化能力 ● 扩展实际业务用例 ● 进一步降低数据分析和沟通的门槛 随着AI不断重塑人们处理数据的方式，ChartGen AI 旨在成为原始信息与业务理解之间的关键桥梁。 新闻垂询 Shirley Song shirley [at] ada.im +65 6226 2377 新加坡罗宾逊路120号 #13-01 邮编 068913 SINGAPORE 068913 本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China ACN Newswire

CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

February 24, 2026
SHENZHEN, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product's review process for marketing approval in the AD indication.Impressive phase III trial data in ADIts Priority Review is expected to accelerate its NDA approvalRuxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product's expansion into multiple therapeutic areas.Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.Building an integrated AD solution,strengthening Dermavon’s leadership in dermatologyAD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines JCN Newswire

TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines

February 24, 2026
TOKYO, Feb 24, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL GROUP Co., Ltd. (Head office: Chuo-ku, Tokyo; Group CEO: Koichiro Tanaka) will provide and donate gold, silver, and bronze medals to the top three men and women finishers of the marathon and wheelchair marathon events at the Tokyo Marathon 2026. The Tokyo Marathon 2026 is organized by the Tokyo Marathon Foundation and will be held on March 1, 2026.Design Representing All the Participants in the Event with Woven LinesThe medals were designed based on the concept of the Tokyo Marathon: The Day We Unite. On the front of the medal, the logo type is placed horizontally above the event logo pattern, which represents “runners, supporters, and cheerers,” to express the image of the Tokyo Marathon, which is held based on the involvement of many people, including runners, as well as volunteer staff and cheerers.On the back of the medal, the name of the event, Tokyo Marathon 2026, is written in Braille, and the words “FINISHER” and the event date are engraved, along with TANAKA’s logo. The medal’s ribbon design continues the 2016 design and is based on the event logo, which resembles a tapestry of lines woven together to represent all the runners, volunteers, and spectators.Sustainability InitiativesThe Tokyo Marathon 2026 is advancing sustainability initiatives centered on “waste reduction,” “environmental conservation,” and “DEI (Diversity, Equity & Inclusion).” In support of this initiative, the medal ribbons are made using recycled polyester. In addition, for the gold medals, the gold plating solution used is from TANAKA’s “RE Series” regenerated precious metals made using only 100% recycled materials. Through these initiatives, TANAKA is helping to make the event more sustainable.About the Tokyo Marathon 2026The Tokyo Marathon 2026 is the 19th edition of one of the largest public participation marathons in Japan. As it will celebrate its 20th anniversary in 2027, the event has evolved further to help all the participants play active roles so that the metropolis of Tokyo unite as one, based on three pillars: “The safest and most secure race in the world,” “The most exciting race in the world,” and “The warmest and most friendly race in the world.” This year, the event has adopted “Run. Tokyo. Own.” as the keyword to express how, on the grand stage of Tokyo, each runner lives their own run and their own story—and how countless individuals coming together create “one Tokyo” for that day and that moment alone.TANAKA has produced the winner and finisher medals for every Tokyo Marathon since the first held in 2007, with this year marking the 19th year. The Tokyo Marathon joined the World Marathon Majors (currently the Abbott World Marathon Majors) in 2013, attracting global attention as one of the world’s seven premier marathons. Other than the Tokyo Marathon, TANAKA has also produced medals for the winners of the Tokyo Legacy Half Marathon, supported the promotion of para sports as an official partner of the Japanese Para Sports Association (JPSA), and produced and sold official commemorative medals for the 1964 Tokyo Olympic Games. As part of its contribution to the realization of an inclusive society and the creation of a healthier society, TANAKA will continue to support the promotion of sports going forward.Overview of the Tokyo Marathon 2026 MedalsWeight, size and materialGold Medal: approx. 100g 65mm in diameter and approx. 3mm: pure silver with gold platingSilver Medal: approx. 100g 65mm in diameter and approx. 3mm: pure silverBronze Medal: approx. 85g 65mm in diameter and approx. 3mm: pure copper platingRace Information of the Tokyo Marathon 2026OrganizerTokyo Marathon FoundationCo-organizersJAAF (Japan Association of Athletics Federations); Tokyo Metropolitan Government;The Yomiuri Shimbun; Nippon Television Network Corporation; Sankei Shimbun Co., Ltd.; The Tokyo Shimbun.Managing OrganizationTokyo Athletics AssociationOperation SupporterTokyo Sports Association for the Disabled; Kanto Para Athletics.Supporting OrganizationsJAPAN SPORTS AGENCY; Ministry of Land, Infrastructure, Transport and Tourism; Japan Tourism Agency; Metropolitan Tokyo Mayors' Council; Japan Sports Association; Japanese Olympic Committee; Japanese Para Sports Association;Japan Para Athletics; Nippon Keidanren (Japan Business Federation);KEIZAI DOYUKAI (Japan Association of Corporate Executives);The Tokyo Chamber of Commerce and Industry; Tokyo Medical Association;Tokyo Disaster Prevention & Emergency Medical Service Association;Tokyo Private Ambulance Call Center Registered Companies Liaison Council;TOKYO NURSING ASSOCIATION; Tokyo Convention & Visitors Bureau;Tokyo Federation of Neighborhood Associations;Tokyo Federation of Shopping Center Promotion Associations & Tokyo Federation of Shopping Centers; Tokyo Sports Association; Community Sport Leaders Tokyo; Metropolitan Expressway Co., Ltd; The Hochi Shimbun; Radio Nippon Co., Ltd.;Sankei Sports; Nippon Broadcasting System, Inc.; The Tokyo Chunichi Sports.Presenting PartnerTokyo Metro Co., Ltd.Official PartnersSTARTS CORPORATION INC.; Mastercard; OujiSeiyaku Co., Ltd.;ASICS Japan Corp.; Otsuka Pharmaceutical Co., Ltd.;KINTETSU INTERNATIONAL; SEIKO GROUP CORPORATION;The Dai-ichi Life Insurance Company, Limited; McDonald's Company (Japan), Ltd.; Mizuho Bank, Ltd.; Kokumin Kyosai co-op (National Federation of Workers and Consumers Kyosai Cooperatives); Hisamitsu Pharmaceutical Co., Inc.;Kao Corporation; Earth Corporation; Porsche Japan K.K.; realbuzz; VENEX Co., Ltd.; NIHON KOHDEN CORPORATION; KOYOU RENTIA Co., Ltd.; Fanplus, Inc.;Shimizu Octo, Inc.; SAGAWA EXPRESS CO., LTD.;TANAKA PRECIOUS METAL GROUP Co., Ltd.; Rokko Butter, Co., Ltd.;Hibino Corporation; Photocreate Co., Ltd; ASUENE Inc.;DateSunday, March 1, 2026*The race information is current as of the time this press release was published. For the latest information, please check the Tokyo Marathon official website.About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ended December 2024 were 846.9 billion yen.TANAKA PRECIOUS METAL GROUP Co., Ltd.TANAKA Corporate Websitehttps://www.tanaka.co.jp/english/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.co.jp/support/req/other_contact_e/index.htmlPress Release: https://www.acnnewswire.com/docs/files/20260224_EN.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More

GDS宣布特别股东大会及其他股东会议延期，将于2026年3月10日重新召开

February 24, 2026
(SeaPRwire) - 中国上海，2026年2月24日 -- GDS Holdings Limited（简称"GDS Holdings"、"GDS"或"公司"）（NASDAQ: GDS；HKEX: 9698），中国领先的高性能数据中心开发商和运营商，今日宣布，根据公司于2026年1月26日发布的先前新闻稿（"先前披露"），股东特别大会（"EGM"）已于2026年2月24日下午4:00（中国标准时间）（即2026年2月24日凌晨3:00（美国东部时间））在中国上海市浦东新区洲海路999号森兰国际C座5层北京会议室召开。A类普通股股东会议于2026年2月24日下午4:30（中国标准时间）在同一地点召开，A系列优先股股东会议于2026年2月24日下午5:00（中国标准时间）在同一地点召开，B系列优先股股东会议于2026年2月24日下午5:30（中国标准时间）在同一地点召开，B类普通股股东会议（与A类普通股股东会议、A系列优先股股东会议及B系列优先股股东会议合称"股东会议"）于2026年2月24日下午6:00（中国标准时间）在同一地点召开。 根据公司章程第64条的规定，并为使股东有更多时间审议先前披露中关于修订公司章程的提案，各股东会议主席正式决定休会（"延期会议"），各会议重新召开的时间为2026年3月10日，地点和时间不变。 为免疑义，先前披露中载列的提案和决议保持不变，将在延期会议上进行审议，并在认为适当时予以通过。 股权登记日不变 根据先前披露，公司董事会已确定2026年2月9日（中国标准时间）营业结束时为股权登记日，以确定有权收到股东会议或任何延期或推迟会议通知并投票的普通股和可转换优先股持有人。 由于延期会议是股东会议的延续，股权登记日将不作变更。 委托投票卡 委托投票卡对延期会议仍然有效并适用。 对于尚未提交委托投票卡的普通股持有人，请按照卡上印制的说明填写委托投票卡，并在延期会议召开前至少48小时通过邮寄或亲手交付至香港湾仔皇后大道东183号合和中心17M楼Computershare Hong Kong Investor Services Limited。 任何已按卡上印制的说明正式填写并交回的委托投票卡对延期会议仍然有效，因此无需再次提交。 如果任何已正式填写并交回委托投票卡的普通股持有人选择重新提交委托投票卡，则在延期会议召开时间前不少于48小时通过邮寄或亲手交付至Computershare Hong Kong Investor Services Limited的最后一份按卡上印制的说明正式填写并交回的委托投票卡，将撤销并取代该持有人此前提交的所有委托投票卡。 除上述公告外，先前披露中载列的所有其他信息保持不变。 载有待提议的决议及寻求股东通过的股东特别大会通知及各股东会议通知、委托投票说明书及委托投票卡的副本，可在公司网站的投资者关系栏目http://investors.gds-services.com、美国证券交易委员会网站及香港交易所网站上查阅。 关于GDS Holdings Limited GDS Holdings Limited（NASDAQ: GDS；HKEX: 9698）是中国领先的高性能数据中心开发商和运营商。公司的设施战略性地分布在需求集中的高性能数据中心服务关键枢纽地区。公司的数据中心具有大净建筑面积、高电力容量、密度和效率，以及所有关键系统的多重冗余。公司是运营商和云中立的，使客户能够接入主要电信网络以及托管在其众多设施中的中国最大和全球公有云。公司拥有25年的服务交付记录，成功满足了中国一些规模最大、要求最严格的外包数据中心服务客户的需求。公司的客户群主要包括超大规模云服务提供商、大型互联网公司、金融机构、电信运营商、IT服务提供商以及大型国内私营部门和跨国企业。公司还持有DayOne Data Centers Limited的少数股权，后者是一家总部位于新加坡的超大规模数据中心平台。 投资者和媒体垂询，请联系： GDS Holdings LimitedLaura Chen电话：+86 (21) 2029-2203电邮：ir@gds-services.com Piacente Financial CommunicationsRoss Warner电话：+86 (10) 6508-0677电邮：GDS@tpg-ir.com Brandi Piacente电话：+1 (212) 481-2050电邮：GDS@tpg-ir.com GDS Holdings Limited本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More

BioNTech将于2026年3月10日公布2025年第四季度及全年财务业绩和企业最新动态

February 24, 2026
(SeaPRwire) - 德国美因茨，2026年2月24日 -- （纳斯达克股票代码：BNTX，“BioNTech”或“公司”）将于2026年3月10日（周二）公布其2025年第四季度及全年财务业绩。此外，公司将于当日美国东部时间上午8:00（欧洲中部时间下午1:00）举办电话会议和网络直播，供投资者、金融分析师及公众讨论其财务业绩并提供企业最新动态。 如需通过电话参与直播电话会议，请通过此链接注册。注册后将提供拨入号码和PIN码。建议至少提前一天注册。网络直播的幻灯片演示文稿和音频将通过此链接获取。 参与者还可通过公司网站投资者关系部分的“Events & Presentations”页面（网址：）访问电话会议的幻灯片和网络直播。网络直播的重播将在会议结束后不久提供，并在公司网站上存档30天。 关于 BioNTech Biopharmaceutical New Technologies（BioNTech）是一家全球下一代免疫治疗公司，致力于开发用于癌症和其他严重疾病的新型研究性疗法。BioNTech 利用广泛的计算发现和治疗模式，旨在快速开发新型生物制药。其多元化的肿瘤候选产品组合旨在覆盖癌症的整个病程，包括 mRNA 癌症免疫疗法、下一代免疫调节剂和靶向疗法（如抗体药物偶联物（ADC）和创新型嵌合抗原受体（CAR）T 细胞疗法）。基于其在 mRNA 开发领域的深厚专业知识及内部制造能力，BioNTech 与其合作者正在研究和开发针对多种传染病的多款 mRNA 疫苗候选物，同时推进其多元化的肿瘤学管线。BioNTech 已与多家全球及专业制药合作伙伴建立广泛合作关系，包括 Bristol Myers Squibb、Duality Biologics、Fosun Pharma、Genentech（罗氏集团成员）、Genmab、MediLink、OncoC4、Pfizer 和 Regeneron。 如需了解更多信息，请访问 。 联系方式 投资者关系Douglas Maffei 博士 媒体关系Jasmina Alatovic本文由第三方内容提供商提供。SeaPRwire (https://www.seaprwire.com/)对此不作任何保证或陈述。 分类: 头条新闻,日常新闻 SeaPRwire为公司和机构提供全球新闻稿发布，覆盖超过6,500个媒体库、86,000名编辑和记者，以及350万以上终端桌面和手机App。SeaPRwire支持英、日、德、韩、法、俄、印尼、马来、越南、中文等多种语言新闻稿发布。
More
康哲药业（867.HK/8A8.SG）：创新药磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症中国上市许可申请获受理并获纳入优先审评 ACN Newswire

康哲药业（867.HK/8A8.SG）：创新药磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症中国上市许可申请获受理并获纳入优先审评

February 24, 2026
深圳, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司 （"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）已于2026年2月24日获得中国国家药品监督管理局（NMPA）受理磷酸芦可替尼乳膏（"产品"）轻中度特应性皮炎（"AD"）的新药上市许可申请（NDA）。产品拟用于其他外用药控制不佳或不建议使用时，非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗。且该项NDA因"符合儿童生理特征的儿童用药品新品种、剂型和规格"，已获得NMPA药品审评中心批准纳入优先审评品种名单，有望加快产品AD适应症上市审评进程。特应性皮炎III期临床数据亮眼，优先审评加速上市磷酸芦可替尼乳膏已于2026年1月获得NMPA批准上市，成为中国批准的首款且唯一用于白癜风治疗的靶向药。此次增加AD适应症NDA获受理，是产品向多治疗领域拓展的关键里程碑。磷酸芦可替尼乳膏已在轻中度AD的一项随机、双盲、安慰剂对照中国三期药物临床研究取得积极结果：- 疗效优异：产品成功达到主要终点，即使用产品治疗8周，达到研究者整体评估（IGA）评分为0或1分，且较基线改善≥2分的受试者比例，显著高于安慰剂（63.0% vs 9.2%，P
More
Mitsubishi Shipbuilding Ships First Units of Systems for Marine Ammonia-Fueled Engines JCN Newswire

Mitsubishi Shipbuilding Ships First Units of Systems for Marine Ammonia-Fueled Engines

February 24, 2026
Ammonia Fuel Supply System (AFSS) moduleTOKYO, Feb 24, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Shipbuilding Co., Ltd., a part of Mitsubishi Heavy Industries (MHI) Group, has shipped an ammonia fuel supply system (AFSS) and an ammonia gas abatement system (AGAS) for Japan Engine Corporation (J-ENG). Both systems are designed for the first ammonia-fueled marine engine model 7UEC50LSJA-HPSCR manufactured by J-ENG and represent the first units produced by Mitsubishi Shipbuilding. Commissioning work for the systems will begin in due course.The AFSS supplies ammonia fuel to the engine in a stable and safe manner, while the AGAS safely processes surplus ammonia generated during fuel switching from ammonia to conventional fuel oil. Both systems support remote operation and automatic control through an integrated control system, enhancing operational efficiency and safety.The early market introduction of these systems will enable onboard verification combining J-ENG's ammonia fueled marine engine model 7UEC50LSJA-HPSCR, a first mover in next-generation advanced fueled engines, with Mitsubishi Shipbuilding's AFSS and AGAS. This combination is expected to further accelerate decarbonization efforts across the maritime industry.Mitsubishi Shipbuilding will continue strengthening its business structure to meet the growing demand for ammonia-fueled vessels.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
MHI Unveils “DIAVAULT,” a Secure, High Performance Edge Data Center Platform JCN Newswire

MHI Unveils “DIAVAULT,” a Secure, High Performance Edge Data Center Platform

February 24, 2026
TOKYO, Feb 24, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) today announced the launch of DIAVAULT, a newly developed industrial grade edge data center(1) brand.DIAVAULT is a digital infrastructure solution that enables on-site data and AI utilization in an on-premises environment (2). It achieves high security and low latency that are difficult to realize in cloud environments. In addition, it is equipped with a stable power supply and cooling systems, enabling long-term stable operation. DIAVAULT will be a key driver accelerating digital transformation in the industrial sector.BackgroundWith the widespread adoption of IoT and AI, industries increasingly require the ability to process large volumes of data in real time. However, cloud-centric processing faces challenges such as latency and data confidentiality risks. Therefore, the importance of edge computing, which enables fast and distributed processing near devices generating vast amounts of data and the users of this data, is increasing.In response to these challenges, MHI is promoting the development of on-premises digital infrastructure. DIAVAULT, centered on a high-security edge data center that simultaneously achieves high on-site information processing and stable operation, flexibly covers customer needs from small-scale to inference data centers (3) of several megawatts. It provides a range of edge solutions such as inference environments in manufacturing sites, research facilities, defense-related fields, and 5G connectivity to meet low latency demands.Key FeaturesRecently, MHI opened a demonstration AI data center on the premises of Yokohama Hardtech Hub (YHH) established at Mitsubishi Heavy Industries Yokohama Works and started validation of various use cases. This data center has the following features:Servers equipped with the next-generation GPU specialized for AI processing are efficiently cooled by two-phase direct chip cooling (4), achieving powerful computing performance and low PUE (5) with excellent cooling performance.The server room is compact, equivalent to two 20-foot containers, but offers a spacious area for the maintenance of large-depth servers and the CDU (6). It is equipped with an uninterruptible power supply with continuous power feed.Proprietary digital integrated air conditioning control technology optimizes air conditioning and heat sources while monitoring server load, delivering energy-saving effects throughout the year.In addition to robust entry/exit security with two-factor authentication, the entire facility is remotely monitored, enabling stable unmanned operation.Future OutlookBuilding on comprehensive engineering capabilities developed in social infrastructure and data center power, cooling, and digital technologies, MHI is advancing solutions with high resilience and high security to support next-generation generative AI and physical AI. With the deployment of DIAVAULT, MHI will promote the widespread adoption and co-creation of more advanced and reliable AI infrastructure through collaboration with domestic and international partners.(1) A small-scale data center installed close to users and devices.(2) A system in which servers are placed at facilities such as company offices, factories, or research institutes to directly manage and process data, rather than using the cloud.(3) A data center optimized for fast and efficient inference after AI models have been "trained." Equipped with AI accelerators specialized for AI processing.(4) A cooling technology that circulates an electrically insulating two-phase refrigerant (liquid and gas) through a cold plate on semiconductor chips (processors) inside the server, removing heat without using water.(5) Power Usage Effectiveness (PUE) is an indicator of how efficiently a data center uses power. The closer to 1.0, the greater the efficiency.(6) CDU (Coolant Distribution Unit) is a device that circulates, distributes, and adjusts the temperature of coolant to efficiently cool IT equipment such as servers.The Edge Data Center "DIAVAULT" in YHHAbout MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
CanSinoBIO’s Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential ACN Newswire

CanSinoBIO’s Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential

February 24, 2026
HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the “NMPA”), pursuant to which, the supplemental application to expand the age range of applicable population of the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “MCV4”, trade name: Menhycia (R)) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved by NMPA.This approval marks an important step forward, underscoring the public health impact of Menhycia (R) while also strengthening its long-term commercial prospects. Under China’s current national immunization schedule, the final pre-school dose of meningococcal vaccination is administered at six years of age. For a long time, multivalent conjugate vaccine options for children over age three have been relatively limited in the domestic market. The newly approved expansion of the eligible age range helps address this gap, providing broader and more appropriate vaccination options for this population.At the same time, the broader eligible population is expected to further unlock Menhycia (R)’s commercialization prospects, and lay a more solid foundation for the product’s promotion and strategic rollout in international markets.Notably, CanSinoBIO issued its Results Forecast For The Year 2025 recently. Forecasting total revenue of RMB 1.04–1.08 billion, a year-on-year increase of 22.88% to 27.61% and net profit attributable to the shareholders of RMB 24.5–29.0 million—marking a return to profitability. The company noted that Menhycia (R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to drive sustained revenue growth under its innovation-led commercialization strategy. This also signifies that the company is now reaping the commercial benefits of its early investments in vaccine innovation.Leveraging its proprietary platform, first-mover advantages, and accelerating global expansion, the age expansion of Menhycia (R) is expected to further strengthen CanSinoBIO’s competitive position while providing new momentum for sustainable growth. As product coverage broadens and international commercialization advances, the company is well-positioned to enter a new phase of long-term growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More